GlassScriptPhysician profile
Jill E Hippenmeyer
NPI 1598354847
$3,345.22
in general payments reported to CMS, 2019-2025
26 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $713 · 2023: $1,034 · 2024: $1,013 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.88 | 2022-2025 | |
| Novo Nordisk INC | $758.34 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $355.25 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.77 | 2022-2025 | Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $175.91 | 2022-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.68 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $127.54 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $126.42 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.99 | 2022-2025 | Trulance, Xifaxan |
| Pfizer INC. | $70.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $63.90 | 2022-2025 | Farxiga |
| Axsome Therapeutics, INC. | $62.27 | 2024-2025 | Auvelity |
| Amgen INC. | $58.15 | 2022-2024 | Evenity, Prolia |
| Eisai INC. | $43.14 | 2024-2025 | |
| Almatica Pharma LLC | $35.28 | 2023 | Loreev Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $33.96 | 2024 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $29.42 | 2023 | Quviviq |
| Verona Pharma, INC. | $27.40 | 2025 | Ohtuvayre |
| Dexcom, INC. | $27.09 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $25.03 | 2025 | Voquezna |
| Axonics, INC. | $23.78 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.62 | 2023 | |
| Novartis Pharmaceuticals Corporation | $15.08 | 2022 | |
| Antares Pharma, INC. | $13.67 | 2022 | |
| Sanofi Pasteur INC. | $13.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Hippenmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.